HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
The association between narcolepsy and human leukocyte antigen HLA- DQB1*06:02 has been established elsewhere but remains to be investigated among Saudi Arabian patients with narcolepsy.
|
30187366 |
2019 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Carrying HLA-DQB1*06:02 was significantly associated with narcolepsy, odds ratio (OR) 39.4 [95% confidence interval (CI) 11.3, 137], p = 7.9 × 10<sup>-9</sup>.
|
30711515 |
2019 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
HLA-DQB1*0602 forms a heterodimer with HLA-DQA1*0102 and may act as an antigen presenter to the T cell receptors, resulting in narcolepsy susceptibility.
|
28108192 |
2018 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis.
|
30321823 |
2018 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The HLA-DQB1*06:02 allele alone was not sufficient to cause MS patients to develop narcolepsy.
|
28658402 |
2017 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our study aimed to determine the prevalence of HLA-DQB1*0602 allele in Iranian patients with narcolepsy and assess its predictive parameters for diagnosing narcolepsy.
|
29149785 |
2017 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Familial Kleine-Levin Syndrome: A Specific Entity?
|
27253765 |
2016 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
Polygenic risks in narcolepsy were estimated to explain 58.1% (P<sub>HLA-DQB1*06:02</sub>=2.30 × 10<sup>-48</sup>, P<sub>whole genome without HLA-DQB1*06:02</sub>=6.73 × 10<sup>-2</sup>) including HLA-DQB1*06:02 effects and 1.3% (P<sub>whole genome without HLA-DQB1*06:02</sub>=2.43 × 10<sup>-2</sup>) excluding HLA-DQB1*06:02 effects.
|
27305985 |
2016 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the present study, HLA-DQB1 in 664 Japanese narcoleptic subjects and 3131 Japanese control subjects was examined to determine whether HLA-DQB1 alleles located in trans of DQB1*06:02 are associated with narcolepsy.
|
25256355 |
2015 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this paper, we extend an analysis of the effect of HLA-DQB1 on narcolepsy risk published recently by Tafti et al.
|
25325462 |
2015 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Genetic studies confirmed the association with the allele HLA-DQB1*06:02, which is known to be related to sporadic narcolepsy.
|
26123389 |
2015 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population.
|
27081540 |
2015 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This comprehensive genetic study sought to assess variations in CHKB and CPT1B susceptibility genes and HLA-DQB1*06:02 allele status in Turkish patients with narcolepsy and healthy persons.
|
24571861 |
2014 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.
|
25197808 |
2014 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
GWASCAT |
Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic.
|
24204295 |
2013 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our data add further support to the strong association of the HLA-DQB1(∗)06:02 allele with narcolepsy, especially in narcolepsy+cataplexy patients.
|
24157097 |
2013 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
This diagnosis was defined as narcolepsy associated with cataplexy plus HLA-DQB1*06:02 positivity (no cerebrospinal fluid hypocretin-1 results available) or narcolepsy with documented low (≤ 110 pg/mL) cerebrospinal fluid hypocretin-1 level.
|
23649748 |
2013 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy is strongly associated with the HLA DQB1*0602 allele, and its symptoms stem from destruction of hypocretin-secreting neurons in the hypothalamus.
|
22213222 |
2012 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
We investigated the association between birth order and narcolepsy risk in a population-based case-control study in which all study subjects were HLA-DQB1*0602 positive.
|
22281000 |
2012 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
BEFREE |
HLA DQB1*0602 is found in most individuals with hypocretin-deficient narcolepsy, a disorder characterized by a severe disruption of sleep and wake.
|
21292329 |
2011 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy symptom severity varies in a linear manner according to HLA-DQB1*0602 allele status.
|
20120618 |
2010 |
HLA-DQB1
|
0.800 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.
|
20711174 |
2010 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo.
|
19506770 |
2009 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Passive smoking may be a risk factor for narcolepsy in subjects with HLA DQB1*0602.
|
19039244 |
2009 |
HLA-DQB1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
For narcolepsy with HLA-DQB1 *0602, prevalence was 15.3 (95% CI: 12.8-17.9).
|
19013100 |
2009 |